Alpha Cognition Inc.
ACOGHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeAlpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company carries a $171.8M market cap, placing it firmly in the micro-cap category. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Market Cap
$171.8M
Beta
2.33
P/E (TTM)
—
P/E (Fwd)
-12.52
EPS (TTM)
$-1.32
EPS (Fwd)
$-0.63
ROE
-51.7%
ROA
-29.0%
Cash
$54.2M
Total Debt
$0
Free CF
-$21.7M
52W Change
-19.5%
Annual Financials
Cash vs Debt
Where ACOG stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, ACOG finished 32.18% above its 150-day moving average ($6.09) and 29.84% above its 200-day moving average ($6.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACOG overbought or oversold?
At the July 15, 2026 close, ACOG's RSI(14) was 78.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Alpha Cognition Inc. reports $54.2M in cash and $0 in total debt. Free cash flow is running at -$21.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -51.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Alpha Cognition Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Alpha Cognition Inc. and its sector.